Cyclosporine Contraindications in Malignancy

Introduction to Contraindications

The American Academy of Dermatology and other guideline societies recommend that cyclosporine is contraindicated in patients with a history of malignancy because systemic immunosuppression may promote growth and progression of existing or residual neoplasms, particularly lymphomas and melanomas, through both impaired immune surveillance and direct cell-autonomous mechanisms that enhance tumor invasiveness 1, 2

The British Association of Dermatologists states that cyclosporine should be avoided entirely in patients with a history of lymphoma, including cutaneous T-cell lymphoma, due to the 41% incidence of lymphoproliferative disorders in cyclosporine-treated patients and early appearance at 11 months 1, 2
The National Comprehensive Cancer Network recommends that cyclosporine is contraindicated in patients with a history of melanoma, due to aggressive behavior under immunosuppression 1, 2
The American Academy of Dermatology suggests that patients with non-melanoma skin cancer and prior UV exposure should avoid cyclosporine due to increased risk of cutaneous squamous cell carcinoma, particularly in psoriasis patients who received high-dose UV irradiation 3
The Journal of the American Academy of Dermatology recommends careful risk-benefit assessment for patients with a remote history of solid tumors, considering cancer type, stage, time since treatment completion, and consultation with oncology 4

The British Journal of Dermatology notes that transplant patients experience significantly greater immunosuppression intensity with combination regimens, resulting in higher malignancy rates 3
The British Journal of Dermatology also reports that dermatology patients on monotherapy showed no increase in internal malignancy, though expected increases in cutaneous squamous cell carcinoma occurred in those with prior UV exposure 3
The Finnish registry data demonstrated no significant increase in lymphoma or skin cancer incidence relative to the general population in 272 dermatology patients treated with cyclosporine 3
The British Journal of Dermatology warns that combining cyclosporine with phototherapy (PUVA or UVB) is contraindicated due to synergistic long-term risk of non-melanoma skin cancer 3
The American Academy of Dermatology recommends avoiding combination therapy with multiple immunosuppressants, as it results in "over-immunosuppression" with higher incidence of viral infection and malignancy 1